Chih-Yao Hsu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chih-Yao Hsu has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Hung-Yuan Li
Division of Endocrinology and Metabolism, Department of Internal Medicine National Taiwan University Hospital Taipei Taiwan
4 shared publications - Chih-Yuan Wang
School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan
3 shared publications - Ching-Chu Chen
Division of Endocrinology and Metabolism, Department of Medicine, China Medical University Hospital, Taichung 40447, Taiwan
3 shared publications - Horng-Yih Ou
Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
3 shared publications - Chien-Ning Huang
Institute of Medicine, Chung Shan Medical University, Taichung City, Taiwan
2 shared publications - Feng-Chih Shen
Division of Endocrinology and Metabolism, Department of Internal Medicine Kaohsiung Chang Gung Memorial Hospital Kaohsiung Taiwan
2 shared publications
Latest Publications
- Open Access
- 13 November 2024
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 16 (1) , 43-50
Precision medicine in diabetes prediction: Exploring a subgroup‐specific biomarker strategy for risk stratification
Introduction: The early detection of high‐risk individuals is crucial to delay and reduce the incidence of type 2 diabetes. In this study, we aimed to explore the performance of a novel subgroup‐specific biomarker strategy in the prediction of incident diabetes.Materials and Methods: In the Taiwan Lifestyle Cohort Study, adult subjects without diabetes were included and followed for the incidence of diabetes in 2006–2019. The biomarkers measured included blood secretogranin III (SCG3), vascular adhesion protein‐1 (VAP‐1), fibrinogen‐like protein 1 (FGL1), angiopoietin‐like protein 6 (ANGPTL6), and angiopoietin‐like protein 4 (ANGPTL4).Results: Among the 1,287 subjects, 12.2% developed diabetes during a 6 year follow‐up. Blood VAP‐1 was significantly associated with incident diabetes in the overall population (HR = 0.724, P < 0.05), participants under 65 years old (HR = 0.685, P < 0.05), those with a BMI of ≥24 kg/m2 (HR = 0.673, P < 0.05), and females (HR = 0.635, P < 0.05). Blood ANGPTL6 was significantly correlated with incident diabetes in participants aged 65 and older (HR = 0.314, P < 0.05), and blood SCG3 was associated with incident diabetes in those with a BMI of 2 (HR = 1.296, P < 0.05). Two subgroup‐specific biomarker strategies were developed. The gender and BMI‐specific biomarker strategy, using traditional risk factors and blood SCG3 or VAP‐1 in different subgroups, could improve prediction performance, especially the specificity and positive prediction value, compared with the whole‐population strategy using only traditional risk factors or traditional risk factors plus blood VAP‐1.Conclusion: Gender‐ and BMI‐specific biomarker strategy can improve the prediction of incident diabetes. A subgroup‐specific biomarker strategy is a novel approach in the prediction of incident diabetes.
- 13 November 2024
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 16 (1) , 43-50
Open AccessPrecision medicine in diabetes prediction: Exploring a subgroup‐specific biomarker strategy for risk stratification
Introduction: The early detection of high‐risk individuals is crucial to delay and reduce the incidence of type 2 diabetes. In this study, we aimed to explore the performance of a novel subgroup‐specific biomarker strategy in the prediction of incident diabetes.Materials and Methods: In the Taiwan Lifestyle Cohort Study, adult subjects without diabetes were included and followed for the incidence of diabetes in 2006–2019. The biomarkers measured included blood secretogranin III (SCG3), vascular adhesion protein‐1 (VAP‐1), fibrinogen‐like protein 1 (FGL1), angiopoietin‐like protein 6 (ANGPTL6), and angiopoietin‐like protein 4 (ANGPTL4).Results: Among the 1,287 subjects, 12.2% developed diabetes during a 6 year follow‐up. Blood VAP‐1 was significantly associated with incident diabetes in the overall population (HR = 0.724, P < 0.05), participants under 65 years old (HR = 0.685, P < 0.05), those with a BMI of ≥24 kg/m2 (HR = 0.673, P < 0.05), and females (HR = 0.635, P < 0.05). Blood ANGPTL6 was significantly correlated with incident diabetes in participants aged 65 and older (HR = 0.314, P < 0.05), and blood SCG3 was associated with incident diabetes in those with a BMI of 2 (HR = 1.296, P < 0.05). Two subgroup‐specific biomarker strategies were developed. The gender and BMI‐specific biomarker strategy, using traditional risk factors and blood SCG3 or VAP‐1 in different subgroups, could improve prediction performance, especially the specificity and positive prediction value, compared with the whole‐population strategy using only traditional risk factors or traditional risk factors plus blood VAP‐1.Conclusion: Gender‐ and BMI‐specific biomarker strategy can improve the prediction of incident diabetes. A subgroup‐specific biomarker strategy is a novel approach in the prediction of incident diabetes.
- Open Access
- 30 October 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (11)
Clinical care guidance in patients with diabetes and metabolic dysfunction–associated steatotic liver disease: A joint consensus
Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide, affecting >30% of the global population. Metabolic dysregulation, particularly insulin resistance and its subsequent manifestation as type 2 diabetes mellitus, serves as the fundamental pathogenesis of metabolic liver disease. Clinical evidence of the recent nomenclature evolution is accumulating. The interaction and impacts are bidirectional between MASLD and diabetes in terms of disease course, risk, and prognosis. Therefore, there is an urgent need to highlight the multifaceted links between MASLD and diabetes for both hepatologists and diabetologists. The surveillance strategy, risk stratification of management, and current therapeutic achievements of metabolic liver disease remain the major pillars in a clinical care setting. Therefore, the Taiwan Association for the Study of the Liver (TASL), Taiwanese Association of Diabetes Educators, and Diabetes Association of the Republic of China (Taiwan) collaboratively completed the first guidance in patients with diabetes and MASLD, which provides practical recommendations for patient care.
- 30 October 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (11)
Open AccessClinical care guidance in patients with diabetes and metabolic dysfunction–associated steatotic liver disease: A joint consensus
Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide, affecting >30% of the global population. Metabolic dysregulation, particularly insulin resistance and its subsequent manifestation as type 2 diabetes mellitus, serves as the fundamental pathogenesis of metabolic liver disease. Clinical evidence of the recent nomenclature evolution is accumulating. The interaction and impacts are bidirectional between MASLD and diabetes in terms of disease course, risk, and prognosis. Therefore, there is an urgent need to highlight the multifaceted links between MASLD and diabetes for both hepatologists and diabetologists. The surveillance strategy, risk stratification of management, and current therapeutic achievements of metabolic liver disease remain the major pillars in a clinical care setting. Therefore, the Taiwan Association for the Study of the Liver (TASL), Taiwanese Association of Diabetes Educators, and Diabetes Association of the Republic of China (Taiwan) collaboratively completed the first guidance in patients with diabetes and MASLD, which provides practical recommendations for patient care.
- Open Access
- 27 April 2024
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 15 (8) , 1151-1160
Optimizing lipid control in Taiwanese diabetic patients: A collaborative consensus by the Diabetes Association of the Republic of China (Taiwan) and the Taiwanese Association of Diabetes Educators
We present an in‐depth analysis of dyslipidemia management strategies for patients with diabetes mellitus in Taiwan. It critically examines the disparity between established guideline recommendations and actual clinical practices, particularly in the context of evolving policies affecting statin prescriptions. The focus is on synthesizing the most recent findings concerning lipid management in patients with diabetes mellitus, with a special emphasis on establishing consensus regarding low‐density lipoprotein cholesterol treatment targets. The article culminates in providing comprehensive, evidence‐based recommendations tailored to the unique needs of those living with diabetes mellitus in Taiwan. It underscores the criticality of personalized care approaches, which incorporate multifaceted factors, and the integration of novel therapeutic options to enhance cardiovascular health outcomes.
- 27 April 2024
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 15 (8) , 1151-1160
Open AccessOptimizing lipid control in Taiwanese diabetic patients: A collaborative consensus by the Diabetes Association of the Republic of China (Taiwan) and the Taiwanese Association of Diabetes Educators
We present an in‐depth analysis of dyslipidemia management strategies for patients with diabetes mellitus in Taiwan. It critically examines the disparity between established guideline recommendations and actual clinical practices, particularly in the context of evolving policies affecting statin prescriptions. The focus is on synthesizing the most recent findings concerning lipid management in patients with diabetes mellitus, with a special emphasis on establishing consensus regarding low‐density lipoprotein cholesterol treatment targets. The article culminates in providing comprehensive, evidence‐based recommendations tailored to the unique needs of those living with diabetes mellitus in Taiwan. It underscores the criticality of personalized care approaches, which incorporate multifaceted factors, and the integration of novel therapeutic options to enhance cardiovascular health outcomes.
- Open Access
- 29 February 2024
- Published by Elsevier in Primary Care Diabetes
- Vol. 18 (3) , 284-290
The expert consensus on care and education for patients with diabetic kidney disease in Taiwan
- 29 February 2024
- Published by Elsevier in Primary Care Diabetes
- Vol. 18 (3) , 284-290
Open AccessThe expert consensus on care and education for patients with diabetic kidney disease in Taiwan
- Open Access
- 22 February 2024
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 15 (6) , 707-710
Interplay of cardiovascular health and diabetes: Insights into weight management and risk reduction
- 22 February 2024
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 15 (6) , 707-710
Open AccessInterplay of cardiovascular health and diabetes: Insights into weight management and risk reduction
- Open Access
- 14 December 2023
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 123 (3) , 325-330
Advanced maternal age-related clustering of metabolic abnormalities is associated with risks of adverse pregnancy outcomes
- 14 December 2023
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 123 (3) , 325-330
Open AccessAdvanced maternal age-related clustering of metabolic abnormalities is associated with risks of adverse pregnancy outcomes
- Open Access
- 22 August 2023
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 123, S141-S152
Follow-up care and assessment of comorbidities and complications in patients with primary aldosteronism: The clinical practice guideline of the Taiwan Society of aldosteronism
- 22 August 2023
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 123, S141-S152
Open AccessFollow-up care and assessment of comorbidities and complications in patients with primary aldosteronism: The clinical practice guideline of the Taiwan Society of aldosteronism
- 2 May 2023
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 162, 132-139
Effects of heart rate variability biofeedback (HRVBFB) on sleep quality and depression among methamphetamine users
- 2 May 2023
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 162, 132-139
Effects of heart rate variability biofeedback (HRVBFB) on sleep quality and depression among methamphetamine users